{
    "HLUKF": {
        "short_name": "H.LUNDBECK A/S",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "HLUYY": {
        "short_name": "H.LUNDBECK A/S",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "LDB.F": {
        "short_name": "H. LUNDBECK A/S NAM. DK 5",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "LUN.CO": {
        "short_name": "H. Lundbeck A/S",
        "long_name": "H. Lundbeck A/S",
        "summary": "H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S has research collaboration with Enamine Ltd. The company was founded in 1915 and is headquartered in Valby, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Valby"
    },
    "S7C.F": {
        "short_name": "STENOCARE  DK-,08",
        "long_name": "Stenocare A/S",
        "summary": "Stenocare A/S cultivates, produces, imports, and sells prescription-based medical cannabis products in the Danish and European markets. It offers medical cannabis oil products. The company was founded in 2017 and is headquartered in Aller\u00c3\u00b8d, Denmark.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Denmark",
        "city": "Aller\u00c3\u00b8d"
    },
    "STENO.CO": {
        "short_name": "STENOCARE A/S",
        "long_name": "Stenocare A/S",
        "summary": "Stenocare A/S cultivates, produces, imports, and sells prescription-based medical cannabis products in the Danish and European markets. It offers medical cannabis oil products. The company was founded in 2017 and is headquartered in Aller\u00c3\u00b8d, Denmark.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "Denmark",
        "city": "Aller\u00c3\u00b8d"
    }
}